Nifty 17053.95 (0.16%)
Sensex 57260.58 (0.27%)
Nifty Bank 35976.45 (-0.14%)
Nifty IT 34870.75 (0.76%)
Nifty Financial Services 17629.95 (0.09%)
Adani Ports 702.60 (-2.03%)
Asian Paints 3144.30 (0.04%)
Axis Bank 651.10 (-1.61%)
B P C L 367.45 (-2.49%)
Bajaj Auto 3298.20 (-1.09%)
Bajaj Finance 6905.75 (1.45%)
Bajaj Finserv 16890.40 (1.25%)
Bharti Airtel 739.35 (0.08%)
Britannia Inds. 3528.60 (-0.75%)
Cipla 965.00 (-0.18%)
Coal India 154.25 (-1.06%)
Divis Lab. 4921.35 (-0.33%)
Dr Reddys Labs 4697.60 (-1.12%)
Eicher Motors 2413.40 (-0.84%)
Grasim Inds 1683.95 (-0.36%)
H D F C 2713.80 (-1.02%)
HCL Technologies 1133.15 (2.08%)
HDFC Bank 1501.25 (0.76%)
HDFC Life Insur. 683.65 (1.94%)
Hero Motocorp 2490.80 (-1.53%)
Hind. Unilever 2329.40 (-0.24%)
Hindalco Inds. 420.15 (0.76%)
I O C L 118.80 (-1.78%)
ICICI Bank 718.40 (-0.53%)
IndusInd Bank 895.45 (-0.70%)
Infosys 1696.35 (0.28%)
ITC 221.50 (-1.12%)
JSW Steel 625.60 (-0.49%)
Kotak Mah. Bank 2019.60 (2.82%)
Larsen & Toubro 1767.25 (-0.61%)
M & M 850.80 (-0.35%)
Maruti Suzuki 7149.50 (-0.29%)
Nestle India 19000.40 (-1.15%)
NTPC 126.50 (-1.82%)
O N G C 144.10 (-2.04%)
Power Grid Corpn 200.25 (-0.87%)
Reliance Industr 2441.50 (1.20%)
SBI Life Insuran 1136.25 (0.52%)
Shree Cement 25540.05 (-1.56%)
St Bk of India 465.10 (-1.15%)
Sun Pharma.Inds. 751.05 (-2.12%)
Tata Consumer 766.00 (-0.09%)
Tata Motors 461.45 (0.27%)
Tata Steel 1114.75 (0.22%)
TCS 3502.00 (1.60%)
Tech Mahindra 1536.65 (0.61%)
Titan Company 2324.20 (1.39%)
UltraTech Cem. 7388.25 (-0.09%)
UPL 689.35 (-2.05%)
Wipro 630.60 (1.47%)
INFY

Ajanta Pharma Ltd.

₹2075.7
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Ajanta Pharma

  • Master Rating:
  • Ajanta Pharma has an operating revenue of Rs. 3,138.37 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 31% is great, ROE of 21% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 144 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Ajanta Pharma Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Ajanta Pharma Ltd Synopsis

NSE-Medical-Generic Drugs

Ajanta Pharma Lt is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 2718.59 Cr. and Equity Capital is Rs. 17.39 Cr. for the Year ended 31/03/2021. Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059.
  • Market Cap

    INR 17,962.28 Cr

  • Sales

    INR 3,047.66 Cr

  • Shares in Float

    2.60 Cr

  • No of Funds

    183 K

  • Yield

    0.46%

  • Book Value

    6.26

  • U/D Vol Ratio

    0.6

  • LTDebt/Equity

    %

  • Alpha

    0.1

  • Beta

    0.28

Ajanta Pharma Ltd Ownership
Ajanta Pharma Ltd Management

Ajanta Pharma Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 2884.982461.32142.081931.51503.94
Fixed Assets Annual Cr 1626.981580.381423.321098.02912.19
Total Non Current Assets Annual Cr 1695.851634.071471.631196.84973.47
Total Current Assets Annual Cr 1836.211415.081049.881095.01775.07
Total Assets Annual Cr 3532.063049.152521.512291.851748.54
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 331.7974280.6498244.2508218.3718170.0326
ROE Annual % 23.4117.9218.2822.1333.23
ROCE Annual % 30.1324.323.1828.2541.78
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 37.5332.6432.933.9538.87

Ajanta Pharma Ltd Technicals

EMA & SMA

CURRENT PRICE

2075.7 (-0.77)

    • Bullish Moving Averages 3
    • Bearish Moving Averages 13

EMA

  • 20 Day

    2127.1

  • 50 Day

    2161.74

  • 100 Day

    2141.96

  • 200 Day

    2032.31

Ajanta Pharma Ltd Resistance and support

2099.9 PIVOT

  • First Resistance

    2129.81

  • Second Resistance

    2167.81

  • Third Resistance

    2197.7

  • First Support

    2061.9

  • Second Support

    2032

  • Third Support

    1994

  • RSI

    39.52

  • MFI

    32.03

  • MACD

    -31.19

  • MACD signal line

    -25.08

Ajanta Pharma Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 41,202 907,268 22.02%
Week 66,984 4,046,491 60.41%
1 Month 62,254 3,902,693 62.69%
6 Month 82,908 3,788,064 45.69%

Ajanta Pharma Ltd Price change analysis

-43.9

Over 1 month

Low High
2000 2239.1

-142.6

Over 3 month

Low High
2000 2366.3

106.4

Over 6 months

Low High
1900.3 2435

539.6

Over Year

Low High
1527.1 2435

Similar Stocks

News

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) an

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) an

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) a

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 3

Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclo Read More

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 3

Further to our communication dated 29th October 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclo Read More

Blogs

FAQs